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IN a previous paper (Howell, 1958) the inhibitory effect of copper acetate
on the development ofhepatic tumours in rats treated with p-dimethylaminoazo-
benzene (DMAB) was described. Liver function was assessed by means of the
bromsulphalein (BSP) excretion test in the hope of obtaining some biochemical
measure of the rate ofprogression of the liver changes and to determine whether
a correlation could be found between the histological changes in the liver, the type
of tumour and the result of the test. It was hoped to discover whether or not
functional, as well as histological differences, existed between the rats given
DMAB with and without copper acetate.
The BSP test was chosen from the many available tests of liver function for a
variety of reasons. It has been shown by Mateer et al. (1947) to be a reliable
screening test in man with chronic hepatitis, cirrhosis or metastatic carcinoma,
andonewhich couldbeusedto measuretherateofprogression orregressionofthese
disease processes. Treatment of the rat with DMAB causes gradual destruction
ofliver cells and a concomitant fibrosis, and its effects can be compared with those
of chronic hepatitis and cirrhosis in man in this respect. As a method of investi-
gating liver function in experimental animals, the value of the BSP test has been
demonstratedby Drill and Ivy (1944) in dogs treated withcarbontetrachlorideand
by Casals and Olitsky (1946) in mice subjected to various types ofhepatic injury.
More recently its value has again been demonstrated by Koch-Weser, Farber
and Popper (1951), Waldstein, Ettinger and Giges (1957) and by Aterman and
Howell (1959). The test has advantages in that the technique is fairly simple,
so that a large number ofanimals can be tested in a short time, and also that the
dye can be detected in very small quantitites of serum. Furthermore, there is
no evidence that injection of the dye causes additional damage to an already
damaged liver (Mateer et al., 1947).
MATERIALS AND METHODS
Seventy albino rats of a heterozygous strain were used (Laboratory Animals
Bureau Catalogue of Uniform Strains, No. 626, 1953; Birmingham strain).
They were divided into 7 groups containing equal numbers of males and females.
The dietary treatment of each of these groups (Tables I, II and III), together
with the reasons for this arrangement have been given in a previous publication
(Howell, 1958).
BSP tests were not undertaken before the 9th month of treatment. Tests
were performed on many of the available animals during this month, again after
12and 15 months, andatothertimes ifitwasthoughtthatananimalhad developed
a hepatic tumour.
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TABLE I.-Groups 5, 6 and 7. Diets
Number
of rats
.G
Group Male Female
5 5
5 5
5 5
5
6
7
Diet
M + DMAB.
M + DMAB + Cu ac.
M + DMAB + Fe cit.
M = Maize, DMAB = 0 09 per centp- Dimethylaminoazobenzene, Cu ac = 0-5 per cent Copper
acetate, Fe cit = 2 0 per cent Ferric citrate.
TABLE II.-Groups 8, 9, 10 and 11. Diets: DMAB and Copper Acetate
Components Given Separately
Number
of rats
.E
Group Male Female
8 . 5 5
9
10
11
5 5
5 5
5 5
Diet
M + DMAB + Fe cit
M + Cu ac
M + DMAB + Fe cit
M + Cu ac
M + DMAB + Fe cit
M + Cu ac
M + DMAB + Fe cit
CP
Number ofdays
per week
4
3
5
2
6
1
4
3
M = Maize, CP = Cube powder, Fe cit = Ferric citrate, Cu ac = Copper acetate, DMAB =
0*09 per cent p-Dimethylaminoazobenzene.
TABLE III.-Groups 8, 9, 10 and 11. To Show Days of Week on which
DMAB or Copper Acetate Was Given
Group Monday Tuesday Wednesday
8 . Cu ac . DMAB . Cu ac
9 . ,, . ,, .DMAB .
10 .DMAB . .. .
11 . CP . ,, . CP
Basal diet maize, except where CP is indicated.
Thursday Friday
DMAB . Cu ac
,. * ..
Saturday Sunday
. DMAB . DMAB
C,
CP
During the test, with the animal anaesthetised, careful abdominal palpation
enabled tumours to be detected at an earlier stage than was otherwise possible,
and when a tumour was found the animal was usually killed immediately after
completion of the test. Some animals without tumours died shortly after the
completion of the test, as an effect of the test itself. Post-mortem examinations
were made and blocks of liver from tumorous and non-tumorous areas were
preserved. Sections were stained, and liver damage was assessed according to the
methods and criteria previously described (Howell, 1958).
The technique ofthe BSP test has been described in detail in previous publica-
tions (Howell, 1957; Aterman and Howell, 1959). All rats were fasted over-night
and then weighed to the nearest gram. A solution of BSP (G. Gurr and Sons)
was injected into the exposed jugular vein, dosage being calculated on 25 mg./kg.
body weight. Exactly 30 minutes after completion of the injection about 2*0 ml.
of blood was withdrawn by cardiac puncture. The blood was centrifuged and the
colourof thedye was developed in the serum by the additionof 10per cent sodium
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hydroxide. The amount of BSP present in the serum was estimated colori-
metrically in the Unicam spectrophotometer using blanks prepared from saline
and from acidified serum. It should be mentioned that certain rats, with clinically
obvious tumours, were found to have icteric sera, but the results of the test
in these animals were ignored since it was thought that they were likely to be
fallacious.
RESULTS
Normal Rats (BSP Present in Serum 30 Minutes After Injection)
This determination was made on 15 rats with an average weight of 300 g.
The mean value at 30 minutes was 0-322 mg. per 100 ml. serum (range = 0.58
to complete excretion, S.D.= 0.18). It was assumed therefore that BSP in the
serum of a normal rat at 30 minutes would be very unlikely to exceed 1 mg./100
ml. serum, and values of this figure and above were regarded as abnormal;
values below 1 mg./100 ml. serum were regarded as normal.
DMAB-treated Rats
Group 5. Maize and DMAB
The first tests were made after 9 months in 4 of the 5 animals surviving at
this time. Three ofthese, including one with a palpable liver tumour, gave normal
values, i.e. less than 1 mg. /100 ml. serum. The 4th animal, also with a tumour,
had abnormal BSP retention. After 10 months only 2 animals remained, both
with liver tumours, and abnormal BSP retention was found; they had given
normal BSP values at 9 months.
Group 6. Maize, DMAB and copper acetate
All 8 available animals were tested at 10 months. None had palpable liver
tumours and all had normal BSP values. After 15 months the 2 surviving rats
were again tested. Neither rat had a liver tumour and both gave normal BSP
values.
Group 7. Maize, DMAB andferric citrate
Four of the 5 available rats were tested at 9 months. Three of them had
palpable liver tumours, of which one had abnormal BSP retention. The tumour-
free animal gave a normal result. During the 10th month an animal was tested
with an abnormal result; it had a palpable liver tumour. At 12 months the sole
survivor was retested, by which time a tumour had developed and the result
was abnormal.
Group 8. (1) Maize, DMAB and ferric citrate, 4 days per week; (2) maize and
copper acetate, 3 days per week
Three of the available 9 animals were tested at 9 months; none had liver
tumours, and the result was normal in all 3. Six of the available 8 were retested
at 12 months, all with normal results, none having liver tumours. Six were
again tested at 15 months, all with normal results, one of the animals having a
liver tumour at this time.
611J. S. HOWELL
Group 9. (1) Maize, DMAB and ferric citrate, 5 days per week; (2) maize and
copper acetate, 2 days per week
Of6 available rats, 4 were testedat 9 months. Three, including 2 withtumours,
gave normal values; the remaining animal, also with a tumour, gave an abnormal
result. The 3 surviving animals in the group were retested at 11 months and
2 gave normal results ; neither having tumours; the third had a tumour and gave
an abnormal result.
Group 10. (1) Maize, DMAB and ferric citrate, 6 days per week; (2) maize and
copper acetate, 1 day per week
Three rats out of the 9 available were tested at 9 months. Abnormal results
were obtained in 2, both of which had tumours, but the 3rd animal, also with a
tumour, gave a normal result. After 12 months all 6 survivors were tested and
abnormal results were obtained in 2; both had tumours. The 4 animals giving
normal values included 2 with tumours. One ofthe rats tested at 12 months with
a normal result was retested at 13 months, by which time a tumour haddeveloped,
and abnormal BSP retention was found.
Group 11. Maize, DMAB andferric citrate, 4 daysper week; rat cube, 3 days per
week
One rat at 9 months and another at 11 months were tested; both gave normal
results, neither having liver tumours. After 12 months all 6 available animals
were tested, and all gave normal results. After 15 months the same animals were
retested, andagain all had normalresults, although at this time 3 ofthem hadliver
tumours.
Correlation ofBSP Test with Histology
1. Normal BSP test
(a) Microscopical changes in liver of animals without tumours.-Material is
available from 6 rats, which died either at the conclusion or within one week of
the test. Microscopically all showed severe liver cell damage and 3 showed varying
degrees ofregenerative hyperplasia. Marked periportal chronic inflammatory cell
and macrophage infiltration was observed associated with proliferation of bile
ducts, but in only one rat was cirrhosis seen which was early in type (Table IV).
(b) Microscopical changes in liver ofanimals with tumours.-There were 10 rats
in this group, in 5 of which the tumour was confined to one or two lobes; in the
TABLE IV.-Rats Without Tumours Dying Shortly After BSP Test. BSP Values
Correlated with Cirrhosis and Liver Weight
BSP Liver
Dietary (mg./100 ml. weight
Rat No. group serum) (g.) Cirrhosis
1 . 11 . 0-72 . 8
2 . 11 . 0-62 . 10
3 . 10 . 0-61 . 11
4 . 8 . 0-71 . 10
5 . 6 . 0-66 . 10 . ++
6 . 6 . 053 . 11
Mean weight of liver = 10 g.
- no cirrhosis. + + = early cirrhosis.
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remaining 5, tumours of varying size were scattered throughout all lobes of the
liver. The types and combinations of tumours are set out in Table V. Sections of
non-tumorous liver from these animals invariably revealed varying degrees of
liver cell damage. Cirrhosis was present in 7 animals, varying from incipient to
advanced in type, but was absent in the remaining 3. All 10 animals showed
architectural abnormalities of the liver lobule, some showing definite regeneration
nodules. All showed marked periportal chronic inflammatory cell infiltration and
bile duct hyperplasia.
TABLE V.-Normal BSP Retention Correlated with Tumour Type, Cirrhosis and
Liver Weight
BSP Liver
Dietary (mg/100 ml. weight Tumour
Rat No. group serum) (g.) type Cirrhosis
1 . 11 . C.E. . 18 . A
2 . 11 . 0-26 . 14 . H +A . ++
3 11 . C.E. . 18 . H+A . -
4 . 10 . ,, . 12 . A . +
5 10 ,, 30 A + . ++
6 . 9 ,, . 12 . A + C . ++
7 . 9 0-27 . 11 . A . ++
8 . 8 C.E. . 35 . HA+A . -
9 7 0-08 . 18 . M . +++
10 5 0-68 . 15 H+M +++
Mean weight of liver = 18-3 g., C.E. - Complete excretion.
H = hepatoma,A = cystadenoma, M hepatoma + cholangiocarcinoma ,C cholangiofibrosis.
+ Incipient cirrhosis, + + = early cirrhosis, + + + = advanced cirrhosis, - no cirrhosis.
2. Abnormal BSP test
Microscopical changes in the liver.-Gross examination ofthe liver ofthe 11 rats
with tumours and abnormal BSP retention showed that, with the exception of a
singlerat, the liver was diffusely involvedbytumour. Bythis is meant thattumour
nodules were found in all lobes, and whilst one lobe might show a larger tumour
than the others, no definite location of a "primary " tumour could be given.
The exception was an animal with a tumour confined to the right lobe ofthe liver.
The incidence of the various types and combinations of tumours are given in
Table VI. All the rats in this group showed irregular granularity of the surface
of the non-tumorous parts of the liver. Microscopic examination of these areas
invariably showed regenerative hyperplasia, increased cellularity of the portal
tracts and bile duct proliferation. Cirrhosis was present in all these animals,
being advanced in 5 and early in the remaining 5.
DISCUSSION
The results ofthe BSP test in DMAB-treated rats were disappointing and failed
to reveal differences between animals treated with DMAB alone and those treated
withDMABand copperacetate. Furthermore, thetest didnotgiveanyinformation
regarding the severity of the pre-neoplastic changes in the liver. There were 6
animals that were tested after prolonged treatment with DMAB but which had
not produced tumours. BSP excretion in these animals was entirely normal even
though they all showed a severe degree of liver cell damage associated with
regenerativehyperplasia, bile duct hyperplasia and in one instance early cirrhosis.
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TABLE VI.-Abnormal BSP Retention Correlated with Tumour Type
Cirrhosis and Liver Weight
BSP Liver
Dietary (mg./100 ml. weight Tumour
Rat No. group serum) (g.) type Cirrhosis
1 . 5 . 1-35 . 10 . H +A . +++
2 . 5 . 2-31 . 30 . H . +
3 . 5 . 2-71 . 25 . H . +++
4 . 7 . 2-80 . 45 . M . +++
5 . 7 . 1-27 . 65 . M+C . +++
6 . 7 137 . 12 . H . ++
7 . 9 . 3-31 . 65 . M . ++
8 . 9 . 2-15 . 30 . H+C
. +
9 . 10 1*27 . 30 M ++
10 10 . 1-57 . 40 . +A ++
11 . 10 1*00 . 75 . M +A+C ++
Mean weight of liver - 38- 81 g.
H= hepatoma, A= cystadenoma, M= hepatoma + cholangiocarcinoma, C= cholangiofibrosis.
+= Incipient cirrhosis, + += early cirrhosis, +++= advanced cirrhosis.
It was not until tumours had developed that the result of the test sometimes,
but not always, became abnormal. Thus 11 rats with tumours had abnormal
dye retention, but in 10, also with tumours, excretion was normal; there were
no majorhistological differences between these two groups of animals. No parti-
cular type of tumour predominated in either group, although the tumours which
occur earliest in the course of DMAB carcinogenesis, e.g. cystadenomata, tended
to be more frequent in the group with normal BSP excretion. Non-tumorous
liver from both groups invariably showed severe damage, with necrosis of liver
cells, regenerative hyperplasia, bile duct proliferation, and in all but 3 animals
early or advanced cirrhosis. It is of interest that the 3 animals without cirrhosis
were able to excrete the dye completely.
Although there were no majorhistological differences between the animals
with and without abnormal dye retention there was a marked difference in the
weight of the liver which could be correlated with the result of the test. The
mean weight of the liver of the 10 animals with tumours, but with normal BSP
excretion was 18 3g. (Table V), but the mean weight oftheliver ofthe11 rats with
BSPretention andtumours was 38*8g. (Table VI). This difference is statistically
significant (0-02 > P> 0.01). The tumours in the former group were smaller,
more "focal " in distribution and were more often confined to one lobe of the
liver than those in the latter group. The weight of the liver is a function of the
amount oftumourpresent and the amount ofdestruction ofnormal liver parenchy-
ma. The difference in liver size was also reflected in the ease with which a diagnosis
ofhepatic tumour development was made. The rats in the group with the heavier
livers had obvious tumours, whereas the tumours in the other group were only
found when the animals were anaesthetised.
Several points of interest arise from this study. Even in the presence of much
chronic liver damage, associated with regenerative hyperplasia and the develop-
ment of cirrhosis the ability of the liver to excrete BSP is unimpaired for a
considerable time. Even when a tumour develops it is not until by growth and
replacement of a large volume of liver tissue by tumour that the test becomes
abnormal. It is possible that abnormal excretion is dependent upon the ratio
oftumour tonon-neoplastic liver in that this may determine the proportion ofthe
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blood supply shunted away from functional liver tissue to non-functional tumour.
However, even the presence of quite large tumours does not necessarily mean that
BSP excretion will be abnormal since 5 rats with tumours, including 2 with livers
weighing 30 g. or more were able to excrete the dye completely (Table V).
The reason why this test remains normal for such a considerable time is not
clear. In the initial stages ofthe experiment considerable doubt was felt about the
validity ofthe test because of the normal results obtained. A study was therefore
undertaken ofBSP excretion in 15 hypothyroid rats in which the main pathological
feature was fatty change in the liver. BSP excretion was impaired in many of
these animals until thyroid extract was given, when it became normal; this was
followed by renewed impairment when thyroid extract was discontinued (Aterman
and Howell, 1959). Hence it was concluded that the method of testing and the
calculation of results of BSP excretion were reliable.
The value ofliver function tests in human hepatic cancer is disputed. Berman
(1951) in his monograph states that most liver function tests devised thus far are
of doubtful value. Spellberg (1954) in his book states
"that liver function tests
are variable and depend to a great extent on an underlying cirrhosis ", but also
"that the BSP is likely to be increased ". Sherlock (1958) in her text-book
states that the BSP test is positive in hepatic cancer. Spatt and Grayzel (1948),
Schupback and Chappell (1952), Galluzi et al. (1953) and Bersohn (1957) all found
abnormal BSP excretion in their cases of primary hepatic cancer. But Holley
and Pierson (1948) concluded that liver function tests as a rule were disappointing
as a method of diagnosis of primary carcinoma of the liver, and that damage must
be extensive before any appreciable change can be detected in the function tests.
In cases of secondary carcinoma involving the liver there is greater uniformity of
opinion and several workers have agreed that the BSP test is ofvalue in diagnosis,
e.g. Paulson and Wyler (1942), Thomas and Zimmerman (1952), Shay and Siplet
(1954) and Sherlock (1958) and ithas been suggested that the results are abnormal
because of interference with blood supply caused by the secondary deposits.
However, this does not explain the discrepancy ofthe results in primary carcinoma
since the cirrhosis usually associated with this condition would be expected to
cause greater interference with normal blood supply.
The clinical diagnosis ofprimary hepatic cancer in man is notoriously difficult
and usually when the diagnosis is made and liver function tests have been under-
taken the tumour is large and much destruction of liver tissue has occurred.
It is concluded that there is some correlation between the results of BSP excretion
in man and in the experimental animals in that the result of the test depends
toagreatextentonthesize ofthe tumourandonthe amountoftumourreplacement
of liver parenchyma. It is also concluded that the BSP test is of little value in
assessing functional impairment of the rat's liver due to DMAB in the pre-
neoplastic stages.
SUMMAR-Y
Liver function has been assessed by means of the BSP excretion test in rats
treated with DMAB. The results ofthe test, regardless ofthe severity of the liver
damage, were entirely normal until a tumour had developed. Ten rats with
tumours had normal BSP excretion and 11 rats, also with tumours, had abnormal
BSP excretion. Abnormal BSP excretion is independent of tumour type and
underlying liver damage, but apparently depends upon the size of tumour and
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the degree of replacement by tumour of liver tissue. It is suggested that these
results conform with those obtained in human cases of primary hepatic cancer.
I am indebted to Professor J. W. Orr and Dr. D. Hamer for valuable help
and advice throughout this investigation. I am also indebted to the Birmingham
Branch of the British Empire Cancer Campaign and to the Medical Research
Fund ofthe United Birmingham Hospitals for support ofthis work.
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